TAM
FATE icon

Titleist Asset Management’s Fate Therapeutics FATE Stock Holding History

Titleist Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,000
Closed -$23.9K – 386
2025
Q3 		$23.9K Hold
19,000
– – ﹤0.01% 315
2025
Q2 		$21.3K Buy
+19,000
New +$22.1K ﹤0.01% 319

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Titleist Asset Management's FATE Position: Q4 2025 in Review

Titleist Asset Management sold out of Fate Therapeutics (FATE) in Q4 2025, closing a stake of 19,000 shares — an estimated $23.9K sold.

Titleist Asset Management first reported a position in FATE in Q2 2025 and held it in 2 quarters. The position peaked at $23.9K in Q3 2025. 146 funds tracked by Wall St. Rank hold FATE as of Q4 2025.

  • Titleist Asset Management reported no remaining Fate Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Titleist Asset Management sold 19,000 Fate Therapeutics shares in Q4 2025, an estimated $23.9K.
  • Titleist Asset Management first reported a position in Fate Therapeutics in Q2 2025 and held it in 2 quarters.
  • Titleist Asset Management's Fate Therapeutics position peaked at $23.9K in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2025.

Based on Titleist Asset Management's 13F filing for Q4 2025, filed 12 Feb 2026.